All In Biotech

Drug Trial Radar · NCT04529772

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤75 Years With Previously Untreated Non-GCB DLBCL

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 611 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

611

Actual

Start

Oct 8, 2020

Primary completion

Feb 22, 2027

Study completion Feb 22, 2027

Sponsor

Lead sponsor
Acerta Pharma BVAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
AstraZeneca
First posted
Aug 28, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 3 randomized, double-blind, placebo-controlled, study assessing the efficacy and safety of acalabrutinib plus rituximab,cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP in subjects ≤75 years of age with previously untreated non-germinal center diffuse large B-cell lymphoma.

Conditions

  • Diffuse Large B-Cell Lymphoma

Interventions

  • acalabrutinibDrug

    Investigational Product

  • placeboDrug

    Placebo comparator

  • PrednisoneDrug

    Investigational Product

  • RituximabDrug

    Investigational Product

  • CyclophosphamideDrug

    Investigational Product

  • VincristineDrug

    Investigational Product

  • DoxorubicinDrug

    Investigational Product

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) per the Lugano Classification for NHL in Arm A compared to Arm BTime frame: at every single visit up to 60 months

Locations

245 sites in 23 countries. Site status is shown where the registry gives one.

  • Research Site

    Tucson, Arizona

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Irvine, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Norwich, Connecticut

  • Research Site

    Fort Myers, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    St. Petersburg, Florida

  • Research Site

    Tallahassee, Florida

  • Research Site

    West Palm Beach, Florida

  • Research Site

    Fort Wayne, Indiana

  • Research Site

    Des Moines, Iowa

  • Research Site

    Wichita, Kansas

  • Research Site

    Louisville, Kentucky

  • Research Site

    Baltimore, Maryland

  • Research Site

    Grand Rapids, Michigan

  • Research Site

    Minneapolis, Minnesota

  • Research Site

    St Louis, Missouri

  • Research Site

    Albany, New York

  • Research Site

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    Stony Brook, New York

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Winston-Salem, North Carolina

  • Research Site

    Eugene, Oregon

  • Research Site

    Portland, Oregon

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Nashville, Tennessee

  • Research Site

    Fort Sam Houston, Texas

  • Research Site

    Lubbock, Texas

  • Research Site

    Salem, Virginia

  • Research Site

    Adelaide, Australia

  • Research Site

    Camperdown, Australia

  • Research Site

    Darlinghurst, Australia

  • Research Site

    Heidelberg, Australia

  • Research Site

    Hobart, Australia

  • Research Site

    Kogarah, Australia

  • Research Site

    Nedlands, Australia

  • Research Site

    Westmead, Australia

Showing 40 of 245 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.